Key regions: France, India, United Kingdom, South Korea, Japan
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. The disease is more prevalent in women than men and often affects individuals between the ages of 20 and 40. In Russia, the MS market has experienced significant growth in recent years.
Customer preferences: Patients in Russia prefer treatments that are effective, affordable, and have minimal side effects. They also prefer treatments that can be administered orally rather than through injections. Patients are becoming more knowledgeable about the disease, and they are seeking out new treatments that offer better efficacy and safety profiles.
Trends in the market: The MS market in Russia has experienced significant growth in recent years due to the increasing prevalence of the disease and the introduction of new treatments. The market has seen a shift towards oral treatments, which are becoming more popular among patients. The market has also seen an increase in the use of biosimilars, which offer a more affordable option for patients.
Local special circumstances: Russia has a high prevalence of MS, with an estimated 120,000 people living with the disease. The country also has a large population of people with disabilities, which has led to increased government support for MS patients. The government provides free medications, rehabilitation services, and financial assistance to MS patients. This has helped to increase access to treatment and improve patient outcomes.
Underlying macroeconomic factors: Russia's pharmaceutical market is growing rapidly, driven by an aging population and increasing healthcare spending. The government has implemented policies to support the development of the pharmaceutical industry, including tax incentives and funding for research and development. The MS market is expected to continue to grow in Russia as the population ages and the prevalence of the disease increases. However, the market is also becoming more competitive, with the entry of new players and the increasing use of biosimilars. Companies will need to continue to innovate and develop new treatments to remain competitive in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
